Journal of Oncology Pharmacy Practice最新文献

{"title":"Efficacy and safety of adjuvant capecitabine and pembrolizumab in early-stage triple-negative breast cancer after standard neo-/adjuvant chemotherapy: A meta-analysis of phase III studies.","authors":"Wala Ben Kridis, Afef Khanfir","doi":"10.1177/10781552251415135","DOIUrl":"10.1177/10781552251415135","url":null,"abstract":"<p><p>BackgroundTriple-negative breast cancer (TNBC) is a subtype of breast cancer with high recurrence rates and poor prognosis. Capecitabine and pembrolizumab are emerging therapies aimed at improving survival outcomes in early-stage TNBC. This meta-analysis compares the efficacy of capecitabine and pembrolizumab in improving disease-free survival (DFS) and overall survival (OS) in early-stage TNBC.MethodsA systematic literature search identified four major randomized controlled trials (RCTs): CREATE-X, GEICAM, KEYNOTE-522, and SYSUCC-001. These studies investigated the efficacy of capecitabine and pembrolizumab in combination with chemotherapy in early-stage TNBC patients. Data on DFS and OS were pooled using a random-effects model, and heterogeneity was assessed using the I² statistic.ResultsThe pooled analysis included 3133 participants across four trials. For OS, pembrolizumab demonstrated a significant benefit with a hazard ratio (HR) of 0.66 (95% CI: 0.64-0.79), indicating a 34% reduction in the risk of death. Capecitabine showed mixed results across studies, with a pooled HR of 0.75 (95% CI: 0.55-1.03). The pooled HR across these studies, calculated using a random-effects model, was found to be 0.69 (95% CI: 0.64 to 0.79). For DFS, pembrolizumab provided a consistent benefit (HR: 0.63, 95% CI: 0.43-0.93), while capecitabine resulted in a significant reduction in recurrence risk (HR: 0.67, 95% CI: 0.52-0.88).ConclusionThis meta-analysis demonstrates that pembrolizumab significantly improves survival outcomes in early-stage TNBC. Capecitabine also provides benefit, especially in DFS, but its impact on OS concerns residual disease. Further studies should explore optimal treatment regimens and combinations, as well as long-term survival data.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"1361-1369"},"PeriodicalIF":1.3,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145966400","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The use of medicinal plants by cancer patients receiving chemotherapy: A cross-sectional study at a referral oncology hospital in Morocco.","authors":"Aichetou Bouh, Slimane Mehdad, Nouriya El Ghoulam, Daoud Daoudi, Ahmed Oubaasri, Fatima Zahra El Mskini, Asmae Labyad, Hinde Iraqi, Souad Benaich, Rachida Hassikou, Hassan Errihani, Saber Boutayeb","doi":"10.1177/10781552251331920","DOIUrl":"10.1177/10781552251331920","url":null,"abstract":"<p><p>Background and aimThe high cost of cancer treatment and adverse side effects of drug therapy remain major health issues worldwide. Medicinal plants (MP) can be used to promote new, safe, and effective anticancer medications. This study aimed to estimate the prevalence of MP use among cancer patients, investigate its association with sociodemographic and clinical factors, and provide available information about the species used.Materials and methodsThis was a cross-sectional study among 508 patients undergoing chemotherapy. Sociodemographic data and information on MPs used in cancer treatment were collected using face-to-face interviews and a questionnaire. Clinical data were obtained from the hospital database. Ethnobotanical indices, including relative citation frequency, informed consensus factor, and fidelity level, were determined for data analysis.Results43.2% of patients used MPs. Of these, 66.3% did not disclose information about MPs to their physicians, 54% experienced improvements, and 6% reported undesirable side effects associated with using MPs. There was a significant association of MPs use with disease duration (<i>P </i>= 0.037) and cancer type (<i>P </i>< 0.001). 27 plant species belonging to 17 families were identified, with Lamiaceae, Apiaceae, and Fabaceae being the most common. The most used species were <i>Origanum compactum benth</i>., <i>Marrubium vulgare</i> L., <i>Trigonella foenum-graecum</i> L., <i>Aloysia citriodora</i>, and <i>Rosmarinus officinalis</i> L.ConclusionThis study showed a high prevalence of MPs use among patients undergoing chemotherapy. Although further studies are needed to investigate the efficacy and safety of commonly used species, our findings may be used to inform evidence-based guidelines, promote communication between cancer patients and healthcare providers, and develop new medicinal plants.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"1214-1228"},"PeriodicalIF":1.3,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144007730","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Methodological considerations in a real-world study of first-line nivolumab plus ipilimumab for metastatic renal cell carcinoma.","authors":"Saptanil Das, Archana Dhyani, Rajnish Kumar, Heena Arora","doi":"10.1177/10781552261458263","DOIUrl":"10.1177/10781552261458263","url":null,"abstract":"","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"1404-1405"},"PeriodicalIF":1.3,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148218168","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-world efficacy and tolerability of axitinib + pembrolizumab in the treatment of renal cell carcinoma.","authors":"Kyle Ritter, Malgorzata Strojny, Jane McCullough, Jenn Law","doi":"10.1177/10781552251331576","DOIUrl":"10.1177/10781552251331576","url":null,"abstract":"<p><p>Combination therapy with immune checkpoint inhibitors (ICIs) and vascular endothelial growth factor tyrosine kinase inhibitors (VEGF TKIs) is standard of care for metastatic renal cell carcinoma (mRCC); however, no head-to-head trials have compared FDA-approved regimens. This project aims to provide real-world data on the safety and efficacy of axitinib + pembrolizumab in the treatment of mRCC and describe management of common treatment-related adverse events. This is a retrospective, observational, quality improvement project conducted at the Robert H Lurie Comprehensive Cancer Center of Northwestern University in Chicago, Illinois. Patients 18 years of age or older with stage IV RCC who received axitinib + pembrolizumab between April 2019 and February 2024 were included. Endpoints included progression-free survival (PFS), overall survival (OS), duration of treatment, subsequent therapies, and safety outcomes. Thirty-one patients received axitinib + pembrolizumab for mRCC. With a median follow-up time of 22.6 months, PFS was 37.4 months and OS was not reached. Ninety-four percent of patients experienced a treatment-related adverse event with 32.3% classified as grade 3 or higher. Fifty two percent of patients required axitinib dose reductions, 70.9% had at least one axitinib dose held, and 70.9% had at least one pembrolizumab dose held. Patients with axitinib dose reductions demonstrated improved OS at one year (92.9% vs. 80%). This retrospective study corroborates the findings of the KEYNOTE-426 trial and further demonstrates the effectiveness of axitinib + pembrolizumab combination therapy in the treatment of mRCC. Dose reductions and holds do not appear to impact treatment efficacy.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"1207-1213"},"PeriodicalIF":1.3,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144026734","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development of an African paediatric oncology pharmacy curriculum: A SIOP Africa 2024 pharmacy workshop output.","authors":"Ebenezer Wiafe, Kauke Bakari Zimbwe, Susan Nyabate Mageto, Shauna Georgia Odongo Arao, Bertrand Pourroy, Tegan Bilse, Agness Chisomo Chitedze, Venus Dadirai Mushininga, Atalay Mulu Fentie, Sherif Kamal, Abilba Frieda Ayinema, Signang Alberic, Lisa Christine Irumba, Jaques van Heerden, Jennifer Ann Geel","doi":"10.1177/10781552251339593","DOIUrl":"10.1177/10781552251339593","url":null,"abstract":"<p><p>BackgroundThe practice of paediatric oncology pharmacy (POP) has been in existence in Africa for several decades. However, most POP practitioners lack formal education and training. Training and credentialing of pharmacists requires the availability of an appropriate curriculum developed to meet local needs. Hence, the African POP technical working group (TWG) of the International Society of Paediatric Oncology (SIOP) embarked on a process to develop a curriculum in POP.MethodThe curriculum development followed a modified Delphi approach: the formalisation of the POP TWG, the initial development of the curriculum, community and stakeholder engagement via a modified Delphi scoring, and the finalisation of the curriculum at the pharmacy workshop of the SIOP Africa Congress in South Africa.ResultsA POP TWG of 23 members with diverse experiences was formed. The initial curriculum, focusing on 36 theoretical and 5 clinical components, was developed. The modified Delphi process restructured the 36 theoretical contents to 27, the 5 clinical contents to 9, and introduced 6 research modules. The theoretical and clinical components were assigned 86 and 240 credit hours respectively, with a research component culminating in a published manuscript. Twenty-eight individuals from 13 countries attended the workshop, resulting in unanimous approval of the curriculum.ConclusionsThe SIOP Africa Pharmacy TWG has developed a POP curriculum specific to Africa. The implementation of the curriculum through African universities and specialist colleges is imperative to reduce the education and training gaps in POP.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"1344-1351"},"PeriodicalIF":1.3,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13578660/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144119938","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of antitumor response to HDAC inhibitors in advanced head and neck cancer: A proportional meta-analysis of clinical trials.","authors":"Allen Pinto, Rajesh Raju, Soumya Patil, Nazah Naurah V, Raushan Kumar Chaudhary","doi":"10.1177/10781552261420755","DOIUrl":"10.1177/10781552261420755","url":null,"abstract":"<p><p>ObjectiveTo study the cumulative proportion of favorable response to Histone Deacetylase Inhibitor (HDACi) among head and neck cancer (HNC) patients.Data SourcesA systematic search (till 17^th-May-2025) was carried out in PubMed, Scopus, and Web of Science databases using \"Head and Neck cancer\" and \"HDAC inhibitors\" as key concept where all the single-arm clinical trials which have clear data on response to HDACi therapy-based RECIST criteria among HNC patients were included in this study. The meta-analysis was performed using R software.Data SummaryThe search resulted in a total of 178 articles, of which 7 studies were found to be relevant based on the inclusion criteria. Out of a total of 101 advanced HNC patients treated with HDACi in single-arm clinical trials, 74 patients showed favorable antitumor response. The pooled cumulative proportion of favorable response with the random effect model was found to be 0.65. Out of these 7 studies, the average proportion of antitumor response was calculated to be 0.758 among HNC patients who received HDACi concurrently with chemotherapy, chemoradiotherapy, and targeted therapy, whereas the average proportion of antitumor response rate to HDACi was 0.485 among priorly treated HNC patients. Vorinostat was the most used HDACi, where the proportion of favorable response was 0.49 compared to the non-vorinostat HDACi (0.77), like valproic acid, panobinostat, and romidepsin.ConclusionThe overall antitumor response to HDACi was found to be 0.65 (65%), which supports the use of HDACi among advanced HNC patients, particularly along with the concurrent chemo/chemoradiotherapy or targeted therapy.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"1380-1390"},"PeriodicalIF":1.3,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146165850","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Safety, effectiveness and pharmacokinetics of high-dose propylene glycol-free melphalan (EVOMELA) with a prolonged infusion as myeloablative conditioning in Chinese multiple myeloma patients undergoing autologous stem cell transplantation: A prospective phase iv study.","authors":"Fengrong Wang, Zhen Cai, Dehui Zou, Wenming Chen, Yongping Song, Chengcheng Fu, Jiong Hu, Ting Yang, Xinchuan Chen, Jinsong Yan, Kaiyan Liu","doi":"10.1177/10781552251336172","DOIUrl":"10.1177/10781552251336172","url":null,"abstract":"<p><p>BackgroundMelphalan formulated with modified cyclodextrin (β-cyclodextrin sulfobutyl ether sodium [BSES]) is widely used before autologous stem cell transplantation (ASCT) in patients with multiple myeloma (MM) because of its favorable solubility and stability versus conventional melphalan, but the efficacy and safety data on Chinese patients with MM who subsequently underwent ASCT are still limited.MethodsIn this prospective, open-label, non-randomized, interventional study, a total of 67 MM patients who were eligible for ASCT were enrolled and assigned to receive 200 mg/m² of Melphalan in two divided doses of 100 mg/m² on Days -3 and -2 before ASCT on Day 0. We evaluated the efficacy, safety and pharmacokinetics (PK) of a prolonged infusion of high-dose BSES-melphalan as the conditioning treatment in the patients.ResultsOverall, 67 patients received melphalan with the median infusion time of 136 min. All patients achieved myeloablation with a median time of 5 days. Median time to neutrophil and platelet engraftments was 11 and 12 days after ASCT, respectively. Within the 65 evaluable patients, 18 patients (27.7%) achieved stringent complete response, 21 (32.3%) achieved complete response, 18 (27.7%) achieved very good partial response, and 3 (4.6%) achieved partial response. No treatment-related mortality (TRM) or adverse events leading to study withdrawal were identified. Prolonged infusion resulted in a lower C_max but comparable AUCs.ConclusionsHigh-dose BSES-melphalan as a conditioning medicine is effective and safe in Chinese patients with MM before ASCT. Prolonging infusion duration may improve the safety without compromising efficacy.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"1280-1288"},"PeriodicalIF":1.3,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144004477","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Safety and tolerability of adjuvant combination treatments following KEYNOTE-522 for early-stage or locally advanced breast cancer with residual disease.","authors":"Julie Lyon Boucher, Katie Lynn Konieczny, Blerina Mukallari, Eva Yifang Pan, Annette Hood, Mara Hofherr","doi":"10.1177/10781552251333650","DOIUrl":"10.1177/10781552251333650","url":null,"abstract":"<p><p>IntroductionPatients with residual invasive carcinoma after neoadjuvant chemotherapy (NACT) for early-stage breast cancer have poor prognoses. The primary objective of this study was to assess the safety and tolerability of adjuvant combination regimens in patients with residual disease after KEYNOTE-522 NACT and surgery.MethodsPatients ≥ 18 years old with triple-negative or hormone-receptor low positive early-stage breast cancer were included if treated with KEYNOTE-522 NACT (modified to dose-dense doxorubicin plus cyclophosphamide (ddAC) in most patients). After definitive surgery, patients were assessed for residual disease and whether they received adjuvant capecitabine or a poly ADP ribose polymerase (PARP) inhibitor concurrently with pembrolizumab or sequentially after pembrolizumab. Adverse effects and dose modifications were collected.ResultsTwenty-two patients received concurrent treatment and eight received sequential treatment. Higher rates of toxicity occurred when two adjuvant agents were administered concurrently compared to sequentially (p-value = 0.166). The concurrent group also had more capecitabine dose adjustments (50% vs. 37.5%), doses held (36.4% vs. 25%) and discontinuations (9.1% vs. 0%) as well as pembrolizumab discontinuations (13.67% vs. 0%). The pathologic complete response (pCR) rates were higher with the use of ddAC than with every-3-weeks doxorubicin plus cyclophosphamide (AC) administered in KEYNOTE-522 (84.7% vs. 64.8%).ConclusionConcurrent therapy with pembrolizumab and capecitabine or olaparib trended towards demonstrating more toxicities than sequential therapy, though not statistically significant. However, concurrent therapy can be completed with dose adjustments or holds per patient tolerability. Additionally, our findings suggest modifying NACT KEYNOTE-522 to ddAC may improve response rates over traditional NACT KEYNOTE-522.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"1256-1265"},"PeriodicalIF":1.3,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144015281","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pharmacist tailored monitoring for patients initiating encorafenib and binimetinib combination therapy.","authors":"Brooke D Looney, Stephanie G White, Josh DeClercq, Autumn D Zuckerman, Leena Choi, Nisha B Shah, Kristen W Whelchel","doi":"10.1177/10781552251334995","DOIUrl":"10.1177/10781552251334995","url":null,"abstract":"<p><p><b>Introduction:</b> Combination therapy with protein kinase B-raf (BRAF) inhibitor, encorafenib, and mitogen-activated extracellular kinase (MEK) inhibitor, binimetinib, is associated with adverse events (AEs) that can lead to therapy changes early in treatment. This study assessed the impact of pharmacist tailored monitoring on therapy changes during the first 90 days after initiation. <b>Methods:</b> This single center, pre-post intervention study included adult patients initiating encorafenib and binimetinib for unresectable or metastatic melanoma, with prescriptions filled through the center's specialty pharmacy or manufacturer's assistance program from July 2018 to December 2019 and April 2021 to December 2022. Beginning April 2021, a tailored monitoring program was implemented. Patients received counseling and a welcome kit at therapy initiation, followed by 6 monitoring calls over the first 90 days aligned with expected AE onset. <b>Results:</b> The number of patients in the pre-intervention (<i>n</i> = 18) and post-intervention (<i>n</i> = 19) cohorts was similar. Fewer patients in the pre-intervention cohort had treatment interruptions (pre 44%, post 58%), dose reductions (pre 39%, post 47%), and discontinuations (pre 11%, post 26%) compared to the post-intervention arm. Most patients reported at least 1 AE within 14 days of initiating therapy (pre 78%, post 95%). The most reported AEs pre- and post-intervention were fatigue (pre 56%, post 68%), nausea (pre 44%, post 74%), and diarrhea (pre 17%, post 47%). Post-intervention, all patients (<i>n</i> = 19) received pharmacist interventions, with patient education (95%) and supportive therapy (68%) being the most frequent. <b>Conclusions:</b> This study supports the HOPA recommendation to follow-up with patients 7-14 days after oral anticancer medication initiation. More studies are needed to evaluate the benefit of increased pharmacist monitoring after the first 2 weeks of therapy.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"1274-1279"},"PeriodicalIF":1.3,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13578670/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143987027","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Contamination on inner walls of syringes used for compounding and administration of hazardous drugs.","authors":"Paul Sessink, Birgit Tans, David Devolder","doi":"10.1177/10781552251332884","DOIUrl":"10.1177/10781552251332884","url":null,"abstract":"<p><p>PurposeThe aim of the study was to measure contamination on inner walls of syringes used for compounding hazardous drugs. As the syringes have an open connection to the environment, evaporation of the drugs could result in environmental contamination and potential exposure of healthcare workers.MethodsForty-three 50 mL BD Plastipak luer lock syringes were collected after single use in compounding hazardous drugs. The inner wall of the barrel was wiped for each syringe. Potential remaining contamination was also measured by liquid extraction to verify the effectiveness of the wiping procedure. Six hazardous drugs were tested. Liquid chromatography tandem mass spectrometry was used for the analysis of cyclophosphamide, doxorubicin, 5-fluorouracil, ifosfamide, and methotrexate. Platinum analysis of cisplatin was performed with voltammetry.ResultsContamination was found for all cyclophosphamide, doxorubicin, ifosfamide, and methotrexate syringes, for eight out of ten 5-fluorouracil syringes, and for none of the cisplatin syringes. Contamination as part of the dose transferred differs between the drugs showing the highest contamination for doxorubicin (median 21.90 ppm) followed by cyclophosphamide (median 1.24 ppm), and ifosfamide (median 0.60 ppm). The lowest contamination was measured for 5-fluorouracil (median 0.02 ppm) and methotrexate (median 0.006 ppm).ConclusionContamination was found on almost all syringes and differs between the drugs indicating some drugs stick more to the inner walls and plunger shafts than others. Contamination implies a potential exposure risk as hazardous drugs could evaporate from the open syringes, contaminate the working environment, and expose healthcare workers.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"1249-1255"},"PeriodicalIF":1.3,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13578643/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144015280","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}